-
Alexion announces stop of Ultomiris CHAMPION-ALS Phase 3 trial
Dear ALS Community, Today, we are sharing the disappointing news that we have made the difficult decision to discontinue the CHAMPION-ALS Phase III trial, based on the recommendation of the… More >>
-
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Decline of SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo Company Is Planning to Provide Continued Access… More >>
-
AB Science announces a voluntary hold in the clinical studies of masitinib worldwide
AB Science SA announced today that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide. This decision follows consultation with the French… More >>
-
Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
Copenhagen – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that the ORARIALS-01 pivotal trial of… More >>
-
Amylyx Pharmaceuticals provides global regulatory update on AMX0035 for ALS
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today provided an update on… More >>
-
Notice to patients with SOD1-ALS regarding access to Biogen Tofersen via Compassionate Use – Early Access Program
Biopharmaceutical company Biogen currently runs the global Phase 3 placebo-controlled clinical trial VALOR, evaluating the safety and efficacy of the antisense oligonucleotide (ASO) Tofersen in SOD1-ALS. The trial became fully… More >>
